RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered protease inhibitor targeting pancreatic cancer and inflammatory gastrointestinal diseases.

RHB-107 presents a new, new non-cytotoxic approach to cancer therapy with several potential mechanisms of action to inhibit tumor invasion and metastasis.

RHB-107 was granted FDA Orphan Drug designation for the adjuvant treatment of pancreatic cancer.

RedHill acquired the worldwide exclusive development and commercialization rights to RHB-107 (excluding China, Hong Kong, Taiwan and Macao) for all indications from Munich-based WILEX AG in June 2014.

To date, RHB-107 has been studied in more than 300 people across 10 clinical studies. WILEX AG completed several clinical studies with RHB-107 for different indications, including several Phase I studies and two Phase 2 proof-of-concept studies. The first Phase 2 study in locally advanced non-metastatic pancreatic cancer and the second study in metastatic breast cancer, established its safety and tolerability profile. The Phase 2 studies with RHB-107 in both indications suggested activity as measured by both tumor response rate and overall survival of patients when administered in combination with first-line chemotherapeutic agents.

RedHill is also evaluating utilization of RHB-107 in several inflammatory gastrointestinal indications.

COVID-19 Development Program

RedHill has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to provide RHB-107 for in vitro testing, to evaluate the drug’s possible mechanism of action and potential activity against COVID-19.

RHB-107 is a serine protease inhibitor active against a number of human trypsins and several other related serine proteases. Inhibition of serine proteases, including trypsins, may inhibit viral attachment and replication and decrease lung damage from viral pneumonia.